Angiogenesis is crucial both in physiological and in pathological conditions. Evidence has been gathered regarding the involvement of angiogenesis in metabolic syndrome-associated disorders, including visceral obesity, dyslipidaemias, atherosclerosis and diabetes. Indeed, metabolic syndrome is characterized by several features that actually modulate angiogenesis such as hypoxia, inflammation, oxidative stress, hormone imbalance or hyperglycaemia. In addition, abnormal expression of angiogenic factors within disorders clustered in the so-called metabolic syndrome, have also been reported. Conversely, the vascular defects broadly observed in metabolic syndrome can be attributed to angiogenic imbalance. In the past years, efforts have been made to develop therapeutic strategies targeting angiogenesis, mostly in oncology. However, recent lines of evidence indicate that angiogenesis is required for many disorders of distinct etiopathogenic origin, namely the ones associated with metabolic syndrome. Taking into account the increasing incidence of this syndrome worldwide, as well as the absence of effective therapeutic strategies, elucidating the angiogenic pathways that play a role in these disorders may be of great interest in order to design novel therapeutic approaches against this major public health challenge.
- Cardiovascular disease
- Endothelial cells
- Smooth muscle cells
- Type 2 diabetes mellitus
This is a preview of subscription content, access via your institution.
Tax calculation will be finalised at checkout
Purchases are for personal use onlyLearn about institutional subscriptions
Unable to display preview. Download preview PDF.
Adamis AP, Aiello LP, D’Amato RA. Angiogenesis and ophthalmic disease. Angiogenesis. 1999; 3: 9–14.
Alfranca A, López-Oliva JM, Genís L, López-Maderuelo D, Mirones I, Salvado D, Quesada AJ, Arroyo AG, Redondo JM. PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGFbeta/Alk5 signaling pathway. Blood. 2008; 112: 1120–8.
Argraves KM, Battey FD, MacCalman CD, McCrae KR, Gåfvels M, Kozarsky KF, Chappell DA, Strauss JF 3rd, Strickland DK. The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes. J Biol Chem. 1995; 270: 26550–7.
Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999; 18: 3964–72.
Bayraktutan U. Nitric oxide synthase and NAD(P)H oxidase modulate coronary endothelial cell growth. J Mol Cell Cardiol. 2004; 36: 277–86.
Beaulieu LM, Whitley BR, Wiesner TF, Rehault SM, Palmieri D, Elkahloun AG, Church FC. Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle. Bioessays. 2007; 29: 1029–38.
Blanchetot C, Boonstra J. The ROS-NOX connection in cancer and angiogenesis. Crit Rev Eukaryot Gene Expr. 2008; 18: 35–45.
Bourassa MG, Berry C. Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes. Curr Atheroscler Rep. 2008; 10: 106–16.
Bray GA. Uses and misuses of the new pharmacotherapy of obesity. Ann Med. 1999; 31: 1–3.
Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci. 2003; 24: 471–8.
Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407: 249.
Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005; 438: 932–6.
Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nature Med. 2000; 6: 1002–3.
Caterson ID, Hubbard V, Bray GA, Grunstein R, Hansen BC, Hong Y, et al. Prevention Conference VII: Obesity, a worldwide Epidemic related to heart disease and stroke: Group III: Worldwide Comorbidities of Obesity. Circulation. 2004; 110: 476–83.
Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006; 354: 610–21.
Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res. 2004; 95: 858–66.
Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, Suzuma K, Bowling NL, Vlahos CJ, Aiello LP, King GL. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation. 200; 105: 373–9.
Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis. 2007; 10: 149–66.
Costa C, Soares R, Reis-Filho JS, Leitão D, Amendoeira I, Schmitt FC. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002; 55: 429–34.
Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J Pathol. 2006; 69: 1505–22.
Dallabrida SM, Zurakowski D, Shih SC, Smith LE, Folkman J, Moulton KS, Rupnick MA. Adipose tissue growth and regression are regulated by angiopoietin-1. Biochem Biophys Res Commun. 2003; 311: 563–71.
Duraisamy Y, Slevin M, Smith N, Bailey J, Zweit J, Smith C, Ahmed N, Gaffney J. Effect of glycation on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: possible relevance to wound healing in diabetes. Angiogenesis. 2001; 4: 277–88.
Erusalimsky JD, Moncada S. Nitric oxide and mitochondrial signaling: from physiology to pathophysiology. Arterioscler Thromb Vasc Biol. 2007; 27: 2524–31.
Fandrey J, Frede S, Jelkmann W. Role of hydrogen peroxide in hypoxia-induced erythropoietin production. Biochem J. 1994; 303: 507–10.
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9: 669–76.
Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttorp N, Sobke A, Herrmann M, Preissner KT, Vajkoczy P, Augustin HG. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006; 12: 235–9.
Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007a; 6: 273–86.
Folkman J. Is angiogenesis an organizing principle in biology and medicine? J Pediatr Surg. 2007b; 42: 1–11.
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285:1182–6.
Frühbeck G. Intracellular signalling pathways activated by leptin. Biochem J. 2006; 393:7–20.
Fukumura D, Ushiyama A, Duda DG, Xu L, Tam J, Krishna V, Chatterjee K, Garkavtsev I, Jain RK. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ Res. 2003; 93: e88–97.
Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem. 1998a; 273: 13313–6.
Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3$′$-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998b; 273: 30336–43.
Hausman GJ, Richardson RL. Adipose tissue angiogenesis. J Anim Sci. 2004; 82: 925–34.
Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L, Plum SM, Williams MS, Strickland DK, Pribluda VS. Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood. 2004; 103: 3374–80.
Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol. 2006; 59: 15–26.
Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia. 2003; 46: 284–287.
Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy. 2006; 26: 168–81.
Jelski W, Szmitkowski M. Effect of ethanol on metabolic syndrome. Pol Merkur Lekarski. 2007; 24: 131–3.
Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002; 2: 301–10.
Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006; 441: 431–6.
Kasza A, Petersen HH, Heegaard CW, Oka K, Christensen A, Dubin A, Chan L, Andreasen PA. Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and alpha2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein. Eur J Biochem. 1997; 248: 270–81.
Kinnula VL, Mirza Z, Crapo JD, Whorton AR. Modulation of hydrogen peroxide release from vascular endothelial cells by oxygen. Am J Respir Cell Mol Biol. 1993; 9: 603–9.
Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004; 10: 625–32.
Konerding M, Ravnic D, Wolloscheck T. Heterogeneity of blood vessels: physiological versus pathological angiogenesis. In: Maragoudakis ME; Papadimitriou E (ed.) Angiogenesis. Basic science and clinical applications, 1st edn. Transworld Research Network. 2007; 1–16.
Kreis T, Vale R (eds). Guidebook to the extracellular matrix, anchor, and adhesion proteins. Oxford University press, UK. 1999.
Lekas M, Lekas P, Latter DA, Kutryk MB, Stewart DJ. Growth factor-induced therapeutic neovascularization for ischaemic vascular disease: time for a re-evaluation? Curr Opin Cardiol. 2006; 21: 376–84.
Leonhardt M, Hrupka B, Langhans W. New approaches in the pharmacological treatment of obesity. Eur J Nutr. 1999; 38: 1–13.
Li A, Cheng G, Zhu GH, Tarnawski AS. Ghrelin stimulates angiogenesis in human microvascular endothelial cells: Implications beyond GH release. Biochem Biophys Res Commun. 2007; 353: 238–43.
Li WW, Hutnik M, Li V. Angiogenesis-based medicine: principles and practice for disease prevention and intervention. In: Maragoudakis ME; Papadimitriou E (ed.) Angiogenesis. Basic science and clinical applications, 1st edn. Transworld Research Network. 2007; 377–417.
Luttun A, Tjwa M, Carmeliet P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann N Y Acad Sci. 2002; 979: 80–93.
Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev. 2003; 23: 117–45.
Masson V, Devy L, Grignet-Debrus C, Bernt S, Bajou K, Blacher S, Roland G, Chang Y, Fong T, Carmeliet P, Foidart JM, Noël A. Mouse aortic ring assay: a new approach of the molecular genetics of angiogenesis. Biol Proced Online. 2002; 4: 24–31.
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399: 271–5.
McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC, Lawrence DA. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem. 2001; 276: 33964–8.
Mikhailenko I, Krylov D, Argraves KM, Roberts DD, Liau G, Strickland DK.Cellular internalization and degradation of thrombospondin-1 is mediated by the amino-terminal heparin binding domain (HBD). High affinity interaction of dimeric HBD with the low density lipoprotein receptor-related protein. J Biol Chem. 1997; 272: 6784–91.
Miyazono K, Usuki K, Heldin CH. Platelet-derived endothelial cell growth factor. Prog Growth Factor Res. 1991; 3: 207–17.
Mullerat J, Wong Te Fong LF, Davies SE, Winslet MC, Perrett CW. Angiogenesis in anal warts, anal intraepithelial neoplasia and anal squamous cell carcinoma. Colorectal Dis. 2003; 5: 353–7.
Ogden CL, Yanovski SZ, Carol MD, Flegal KM. The epidemiology of obesity. Gastroenterology. 2007; 132: 2087–2102.
Ohnishi T, Daikuhara Y. Hepatocyte growth factor/scatter factor in development, inflammation and carcinogenesis: its expression and role in oral tissues. Arch Oral Biol. 2003; 48: 797–804.
Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003; 107: 671–4.
Palacios-Callender M, Hollis V, Mitchison M, Frakich N, Unitt D, Moncada S. Cytochrome c oxidase regulates endogenous nitric oxide availability in respiring cells: a possible explanation for hypoxic vasodilation. Proc Natl Acad Sci USA. 2007; 104: 18508–13.
Polytarchou C, Hatziapostolou M, Poimenidi E, Papadimitriou E. Reactive oxygen species as mediators of angiogenesis signaling. In: Maragoudakis ME, Papadimitriou E (ed.) Angiogenesis. Basic science and clinical applications, 1st edn. Transworld Research Network. 2007; 207–27.
Presta M, Dell’Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005; 16: 159–78.
Rana J, Nieuwdorp M, Jukema J, Kastelein J. Cardiovascular metabolic syndrome – an interplay of obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab. 2007; 9: 329–32.
Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, Pell CL, Johnstone BH, Considine RV, March KL. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation. 2004; 109: 1292–8.
Rocha A, Azevedo I, Soares R. Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells. Angiogenesis. 2007; 10: 279–86.
Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004; 5: 153–65.
Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, Folkman MJ. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA. 2002; 99: 10730–5.
Sasso FC, Torella D, Carbonara O, Ellison GM, Torella M, Scardone M, Marra C, Nasti R, Marfella R, Cozzolino D, Indolfi C, Cotrufo M, Torella R, Salvatore T. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol. 2005; 46: 827–34.
Semenza GL, Shimoda LA, Prabhakar NR. Regulation of gene expression by HIF-1. Novartis Found Symp. 2006; 272: 2–8.
Shoelson SE, Herrero L, Naaz A. Obesity, inflammation and insulin resistance. Gastroenterology 2007; 132: 2169–2180.
Simons M, Ware JA. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov. 2003; 2: 863–71.
Smith-McCune KK, Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res. 1994; 54: 800–4.
Soares R, Balogh G, Guo S, Görtner F, Russo J, Schmitt F. Evidence for the notch signaling pathway on the role of estrogen in angiogenesis. Mol Endocrinol. 2004; 18: 2333–43.
Soares R, Costa C. Angiogenesis and inflammatory diseases: current concepts and therapeutic perspectives. In: Maragoudakis ME; Papadimitriou E (ed.) Angiogenesis. Basic science and clinical applications, 1st edn. Transworld Research Network. 2007; 511–47.
Soares R, Guo S, Görtner F, Schmitt FC, Russo J. 17 beta -estradiol-mediated vessel assembly and stabilization in tumor angiogenesis requires TGF beta and EGFR crosstalk. Angiogenesis. 2003; 6: 271–81.
Stamm C, Kleine HD, Choi YH, Dunkelmann S, Lauffs JA, Lorenzen B, David A, Liebold A, Nienaber C, Zurakowski D, Freund M, Steinhoff G. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J Thorac Cardiovasc Surg. 2007; 133: 717–25.
Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, Charbonneau F, Cohen E, Curtis M, Buller CE, Mendelsohn FO, Dib N, Page P, Ducas J, Plante S, Sullivan J, Macko J, Rasmussen C, Kessler PD, Rasmussen HS. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther. 2006; 13:1503–11.
Sumi M, Sata M, Toya N, Yanaga K, Ohki T, Nagai R. Transplantation of adipose stromal cells, but not mature adipocytes, augments ischemia-induced angiogenesis. Life Sci. 2007; 80:559–65.
Thannickal V, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol. 2000; 279: L1005–28.
Tigno XT, Selaru IK, Angeloni SV, Hansen BC. Is microvascular flow rate related to ghrelin, leptin and adiponectin levels? Clin Hemorheol Microcirc. 2003; 29: 409–16.
Tsigkos S, Papapetropoulus A. The angiopoietins: linking angiogenesis and inflammation. In: Maragoudakis ME; Papadimitriou E (ed.) Angiogenesis. Basic science and clinical applications, 1st edn. Transworld Research Network. 2007; 79–93.
Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett. 2008; 266: 37–52.
Vásquez-Vivar J, Kalyanaraman B, Martásek P, Hogg N, Masters BS, Karoui H, Tordo P, Pritchard KA Jr. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A. 1998; 95: 9220–5.
Vinores S Anti-VEGF therapy for ocular vascular diseases. In: Maragoudakis ME; Papadimitriou E (ed.) Angiogenesis. Basic science and clinical applications, 1st edn. Transworld Research Network. 2007; 467–81.
Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev. 2007; 8: 395–408.
Waypa GB, Marks JD, Mack MM, Boriboun C, Mungai PT, Schumacker PT. Mitochondrial reactive oxygen species trigger calcium increases during hypoxia in pulmonary arterial myocytes. Circ Res. 2002; 91: 719–26.
Weninger W, Uthman A, Pammer J, Pichler A, Ballaun C, Lang IM, Plettenberg A, Bankl HC, Stürzl M, Tschachler E. Vascular endothelial growth factor production in normal epidermis and in benign and malignant epithelial skin tumors. Lab Invest. 1996; 75: 647–57.
Wheeler-Jones C, Abu-Ghazaleh R, Cospedal R, Houliston RA, Martin J, Zachary I. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett. 1997; 420: 28–32.
Whelton H, Harrington J, Crowley E, Kelleher V, Cronin M, Perry IJ. Prevalence of overweight and obesity on the island of Ireland: results from the North South Survey of Children’s Height, Weight and Body Mass Index, 2002. BMC Public Health. 2007; 7: 187.
Wingard D, Barret-Conner E, Criqui M, Suarez L: Clustering of heart disease risk factors in diabetic compared to non-diabetic adults. Am J Epidemiol. 1983; 117: 19–26.
Yamagishi S, Adachi H, Abe A, Yashiro T, Enomoto M, Furuki K, Hino A, Jinnouchi Y, Takenaka K, Matsui T, Nakamura K, Imaizumi T. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab. 2006; 91: 2447–50.
Yamagishi S, Inagaki Y, Nakamura K, Abe R, Shimizu T, Yoshimura A, Imaizumi T. Pigment epithelium-derived factor inhibits TNF-$α$-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol. 2004; 37: 497–506.
Yamagishi S, Nakamura K, Ueda S, Kato S, Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell Tissue Res. 2005; 320: 437–445.
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000; 407: 242–8.
You T, Nicklas BJ, Ding J, Penninx BW, Goodpaster BH, Bauer DC, Tylavsky FA, Harris TB, Kritchevsky SB. The metabolic syndrome is associated with circulating adipokines in older adults across a wide range of adiposity. J Gerontol A Biol Sci Med Sci. 2008; 63: 414–9.
Zorio E, Gilabert-Estellés J, España F, Ramón LA, Cosín R, Estellés A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem. 2008; 15: 923–9.
Editors and Affiliations
© 2009 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Soares, R. (2009). Angiogenesis in the Metabolic Syndrome. In: Soares, R., Costa, C. (eds) Oxidative Stress, Inflammation and Angiogenesis in the Metabolic Syndrome. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-9701-0_5
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-9700-3
Online ISBN: 978-1-4020-9701-0